Search - tctmd.com

Displaying 241 - 260 of 1266

Sort: Relevancy | Date

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Optimal Care Reported in Less Than Half of Adults With ASCVD

Yael L. Maxwell

December 05, 2023

News Daily News

Statin Use Has Plateaued in US Primary Prevention Patients

Michael O'Riordan

December 05, 2023

News Daily News

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

Todd Neale

November 22, 2023

News Daily News

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Michael O'Riordan

November 21, 2023

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

L.A. McKeown

November 17, 2023

News Conference News AHA 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

L.A. McKeown

November 15, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Daily News

For Predicting CV Risk, Life’s Essential 8 Doesn’t Add Much to Simple 7

Caitlin E. Cox

October 23, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

Advertisement

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Optimal Care Reported in Less Than Half of Adults With ASCVD

Statin Use Has Plateaued in US Primary Prevention Patients

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Mortality Risk Varies Among Patients With Very High LDL Levels

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

AI Improves Detection of Cardiomyopathy in Pregnancy

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 2023 News Roundup

For Predicting CV Risk, Life’s Essential 8 Doesn’t Add Much to Simple 7

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content